Jiangsu Yuexing Pharmaceutical Technology

Jiangsu Yuexing Pharmaceutical Technology is a biopharmaceutical company headquartered in Taizhou, China, within the China Medical City industrial cluster. The company specializes in the research, development, and commercialization of innovative small molecule drugs, particularly focusing on oncology, cardiovascular, and metabolic therapeutic areas. Their lead candidate, YX-2102, is a third-generation EGFR inhibitor currently being evaluated in clinical trials for the treatment of non-small cell lung cancer. Beyond its innovative pipeline, Yuexing also develops high-end generic medications to address significant public health needs. The organization integrates a comprehensive R&D platform that spans from early-stage drug discovery to clinical proof-of-concept.